An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
South Africa is seeing a big jump in demand for prescription drugs that help with weight loss, and the medicine Mounjaro is at the front of that surge. Companies there are selling lots more of these medicines, and now Aspen, a South African drugmaker, is getting ready to launch its own version of a popular drug in that class called Ozempic. The story is about rising sales, new local competition, and how these drugs are changing the market. Mounjaro is the brand name for tirzepatide. In simple terms, it’s a man-made version of signals your body uses to control hunger and blood sugar. It acts like hormones that come from the gut after you eat; those signals tell your brain you’re less hungry and help slow how quickly food leaves your stomach. People first used drugs like this to treat type 2 diabetes, because they help control blood sugar. Doctors discovered they also cause weight loss, and that’s why lots of people now use them mainly for losing weight. The news piece is about sales and market moves, not a new scientific study. It reports that sales of weight-loss drugs in South Africa have jumped to about $187 million (that’s the size of the market they mention), with Mounjaro leading the pack. It also says Aspen plans to introduce its own product to compete with Ozempic (semaglutide), which is an established drug in this family. The article is about business trends: who’s buying, which drugs are selling, and which companies are entering the market. It doesn’t present new clinical trial results or claims that a drug is safer or more effective than others—just that demand and competition are rising. This matters because wider availability and local competition can affect price, access, and how doctors prescribe these medicines. For someone struggling with obesity or diabetes, more options could mean better access or lower costs if competition brings prices down. It also matters for health systems and insurers who are suddenly facing higher demand for costly injectable drugs that were once used mainly by people with diabetes but are now prescribed for weight loss too. If you or someone you know is considering one of these drugs, it’s worth knowing that they’re becoming more common and easier to find, but that doesn’t mean they’re right for everyone. There are important caveats and risks. These drugs are prescription medicines with potential side effects like nausea, diarrhea, and other digestive troubles; they can also affect blood sugar and interact with other conditions or medicines. Long-term effects are still being studied, especially when used primarily for weight loss rather than diabetes. Regulatory approvals differ by country and by indication (diabetes versus weight management), so a drug available in one place for weight loss might not be approved for that use elsewhere. Finally, business reports don’t replace medical advice: decisions about these medications should be made with a doctor who knows your health history. Bottom line: South Africa’s market for injectable weight-loss drugs has surged, driven by Mounjaro, and local companies like Aspen are moving in, which could change access and prices—but these are prescription medicines with real risks and trade-offs that need medical guidance.
Source: Business Insider Africa